SCHEMBL5870402

SCHEMBL5870402

CC1OCC(=O)C1NC(=O)C(CC1CCCCC1)OC(=O)N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CTSS P25774 19/20 0.42
CTSL P07711 10/20 0.38
CTSB P07858 2/20 0.37
REN P00797 1/20 0.37
CTSK P43235 6/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5870342 0.83 CTSS (0.35) CTSSCTSLCTSK
SCHEMBL5870291 0.82 CTSS (0.53) CTSSCTSLCTSK
SCHEMBL6957544 0.79 ALDH1A1 (0.40) CTSS
SCHEMBL6702419 0.78 CTSS (0.42) CTSSCTSLCTSBRENCTSK
SCHEMBL8288627 0.77 CTSS (0.41) CTSSCTSLCTSBRENCTSK
SCHEMBL4459425 0.76 CTSS (0.47) CTSSCTSLRENCTSK
SCHEMBL14355739 0.75 CTSS (0.40) CTSSCTSLCTSBRENCTSK
SCHEMBL14347626 0.74 NAAA (0.40) CTSSCTSLREN
SCHEMBL6062496 0.74 CTSS (0.52) CTSSCTSLCTSBCTSK
SCHEMBL6062505 0.74 CTSS (0.52) CTSSCTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132449-B2 Inhibitors of cruzipain and other cysteine proteases AMURA THERAPEUTICS LIMITED (GB) 2006-11-07 US disclosed
US-20040127424-A1 Inhibitors of cruzipain and other cysteine proteases AMURA THERAPUTICS LIMITED (GB) 2004-07-01 US disclosed
EP-1358174-A2 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES Amura Therapeutics Limited (GB) 2003-11-05 EP disclosed
WO-2002057248-A2 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LIMITED (GB) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127424-A1 Inhibitors of cruzipain and other cysteine proteases CPN1, CTRL, CPA1 CTSS 24/4885CTSL 22/4885CTSB 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.